Osteoarthritis pipeline shifting from analgesics to disease-modifying treatments
Conventional analgesics prescribed for osteoarthritis offer inadequate pain relief and are associated with several adverse events.
By
Immunology
Latest in
Immunology
Dragonfly and AbbVie partner to develop immune-mediated disease therapies
Leveraging the TriNKET platform of Dragonfly, the alliance will develop drug candidates for immune-mediated diseases.
NICE questions cost-effectiveness for Adtralza, Rinvoq and Cibinqo
The National Institute for Health and Care Excellence (NICE) does not recommend the agents for the treatment of atopic dermatitis.
By
Pipeline therapies promising better disease management for osteoarthritis
GlobalData has identified drug candidates for osteoarthritis that could shift the competitive landscape and treatment paradigm.
By
Sanofi and IGM partner to develop IgM antibody agonists for six targets
Sanofi will make more than $6bn in development, regulatory, and commercial milestone payments to IGM.
Bacteria and balance: how understanding the vaginal microbiome can help discover new drugs
Imbalance in the vaginal microbiome has been linked to a range of conditions, from UTIs to preterm birth.
By
Pfizer concludes Arena Pharmaceuticals acquisition for $6.7bn
Pfizer will gain access to Arena’s portfolio of various treatment candidates for gastroenterology, dermatology and cardiology.
With Staquis’ exit, PDE-4 class potential in AD is uncertain
Pfizer’s Staquis and other PDE4 therapies for atopic dermatitis may soon be outpaced by treatments with other methods of action.
By